secwatch / observer
8-K filed July 3, 2023, 7:59 PM ET ticker ARTL CIK 0001621221
other confidence high sentiment neutral materiality 0.10

Artelo Biosciences annual meeting elects all 7 directors and ratifies auditor

ARTELO BIOSCIENCES, INC.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ARTELO BIOSCIENCES, INC. shareholders approved Election of Directors at the 2023-06-30 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-06-30
Exact text from the filing
The Class I nominees were elected by the holders of our common stock for a one-year term, to serve until the 2024 annual meeting of stockholders, the Class II nominees were elected by the holders of our common stock for a two-year term, to serve until the 2025 annual meeting of stockholders, and the Class III nominees were elected by the holders of our common stock for a three-year term, to serve until the 2026 annual meeting of stockholders, and in each case, until their respective successor, if any, is duly elected and qualified:
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ARTELO BIOSCIENCES, INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-30 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-06-30
Exact text from the filing
The appointment of Malone Bailey LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified based on the following results of voting: For Against Abstain 1,049,839 41,188 29,212
View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

ARTELO BIOSCIENCES, INC. filing history →

Source: SEC EDGAR
accession 0001640334-23-001207
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.